Sort   by:  
 Page size 
ProteomicsDNR pulse treatment of primary AML
Primary human AML bone marrow sample (newly diagnosed, prior to treatment initation) was obtained from donor after consent and AML blasts were isolated by standard Ficoll centrifugation. AML blasts were pulse-treated with daunorubicine (100 nM, 200 nM, 400 nM) or DMSO control for 1 hour, followed by...
ORGANISM(S): Homo sapiens (Human) 
2022-10-15 | PXD030280 | Pride
Aml Dnr 
ProteomicsPhosphoproteomics of human MV4-11 AML cells treated with Gilteritinib
Internal tandem duplications (ITD) in the receptor tyrosine kinase FLT3 occur in 25% of acute myeloid leukemia (AML) patients and lead to constitutive activation of FLT3, driving leukemia cell survival and proliferation. Quizartinib, crenolanib and gilteritinib are second-generation FLT3 inhibitors ...
ORGANISM(S): Homo sapiens (Human) 
2022-08-25 | PXD023123 | Pride
Human Lc-msms Flt3 Aml 
ProteomicsPhosphoproteomics of primary human FLT3-ITD+ AML cells treated with gilteritinib
Primary human AML cells (newly diagnosed, prior to treatment initation) were obtained from donor after consent and AML blasts were isolated by standard Ficoll centrifugation. AML blasts were treated with FLT3 inhibitor gilteritinib (or DMSO vehicle control) at 10 nM concentration for 6 h, followed b...
ORGANISM(S): Homo sapiens (Human) 
2022-08-25 | PXD034080 | Pride
Aml Gilteritinib Flt3 
ProteomicsTranslatome proteomics of human AML cells treated with FLT3 inhibitors quizartinib, crenolanib, gilteritinib
Internal tandem duplications (ITD) in the receptor tyrosine kinase FLT3 occur in 25% of acute myeloid leukemia (AML) patients and lead to constitutive activation of FLT3, driving leukemia cell survival and proliferation. Quizartinib, crenolanib and gilteritinib are second-generation FLT3 inhibitors ...
ORGANISM(S): Homo sapiens (Human) 
2022-08-25 | PXD023125 | Pride
Human Lc-msms Flt3 Aml 
ProteomicsTranslatome proteomics of primary human FLT3-ITD+ AML cells treated with FLT3 inhibitors quizartinib, crenolanib, gilteritinib
Primary human AML cells (newly diagnosed, prior to treatment initation) was obtained from donor after consent and AML blasts were isolated by standard Ficoll centrifugation. Cells were treated ex vivo with DMSO vehicle control or 10 nM FLT3 inhibitors quizartinib, crenolanib, gilteritinib for 6 hour...
ORGANISM(S): Homo sapiens (Human) 
2022-08-25 | PXD034081 | Pride
Aml Gilteritinib Flt3 Translatome Quizartinib Crenolanib 
UnknownExtended pharmacological thromboprophylaxis and clinically relevant venous thromboembolism after major abdominal and pelvic surgery: international, prospective, propensity score-weighted cohort study.
Not available
S-EPMC11894929 | biostudies-literature
Sort   by:  
 Page size